المساهمون: Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Hematoloji Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı., Özkocaman, Vildan, Demirkaya, Metin, AAH-1854-2021, 6603145040, 24331130000

مصطلحات موضوعية: Oncology, Hodgkin lymphoma, Resistant/relapsed disease, Programmed death 1 (PD-1) blocker, Nivolumab, Brentuxımab vedotın, PD-1 blockade, Adolescent, Adult, Aged, Antibodies, Monoclonal, Antineoplastic, Agents, Disease-free survival, Female, Hodgkin disease, Humans, Immunoconjugates, Male, Middle aged, Retrospective studies, Stem cell transplantation, Young adult, Brentuximab Vedotin, Hodgkin's Disease, Refractory Materials, Mycophenolate mofetil, Programmed death 1 receptor, Steroid

وصف الملف: application/pdf

العلاقة: Makale - Uluslararası Hakemli Dergi; Annals of Oncology; Yurt içi; Sanayi; Beköz, H. vd. (2017). ''Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience''. Annals of Oncology, 28(10), 2496-2502.; https://doi.org/10.1093/annonc/mdx341Test; https://www.sciencedirect.com/science/article/pii/S0923753419349452Test; http://hdl.handle.net/11452/32082Test; 000411827200025; 2-s2.0-85030557671; 2496; 2502; 28; 10

الإتاحة: https://doi.org/10.1093/annonc/mdx341Test
http://hdl.handle.net/11452/32082Test
https://www.sciencedirect.com/science/article/pii/S0923753419349452Test

المساهمون: Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Hematoloji Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı., Özkocaman, Vildan, Demirkaya, Metin, AAH-1854-2021, 6603145040, 24331130000

مصطلحات موضوعية: Oncology, Hodgkin lymphoma, Resistant/relapsed disease, Programmed death 1 (PD-1) blocker, Nivolumab, Brentuxımab vedotın, PD-1 blockade, Adolescent, Adult, Aged, Antibodies, Monoclonal, Antineoplastic, Agents, Disease-free survival, Female, Hodgkin disease, Humans, Immunoconjugates, Male, Middle aged, Retrospective studies, Stem cell transplantation, Young adult, Brentuximab Vedotin, Hodgkin's Disease, Refractory Materials, Mycophenolate mofetil, Programmed death 1 receptor, Steroid

وصف الملف: application/pdf

العلاقة: Makale - Uluslararası Hakemli Dergi; Annals of Oncology; Yurt içi; Sanayi; Beköz, H. vd. (2017). ''Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience''. Annals of Oncology, 28(10), 2496-2502.; https://doi.org/10.1093/annonc/mdx341Test; https://www.sciencedirect.com/science/article/pii/S0923753419349452Test; http://hdl.handle.net/11452/32082Test; 000411827200025; 2-s2.0-85030557671; 2496; 2502; 28; 10

الإتاحة: https://doi.org/10.1093/annonc/mdx341Test
http://hdl.handle.net/11452/32082Test
https://www.sciencedirect.com/science/article/pii/S0923753419349452Test

المساهمون: Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı., orcid:0000-0002-9732-5340, Çubukçu, Erdem, Ölmez, Ömer Fatih, Saraydaroǧlu, Özlem, Akçalı, Ünsal, Kanat, Özkan, Kurt, Ender, Evrensel, Türkkan, Manavoǧlu, Osman, AAJ-1027-2021, AAH-9701-2021, 53986153800, 26435400000, 15074395500, 16027743900, 55881548500, 7006207332, 6603942124, 6602587152

مصطلحات موضوعية: Oncology, Non-small-cell lung cancer, Excision repair cross-complementing 1, Immunohistochemistry, Prognosis, Dna-repair, Chemotherapy, Messenger-RNA, Biomarkers, Resistance, Therapy, Gene, Adult, Aged, Antineoplastic agents, Carcinoma, non-small-cell lung, adjuvant, Cisplatin, Disease-free survival, DNA-binding proteins, Endonucleases, Female, Humans, Lung neoplasms, Male, Middle aged, DNA Repair, Value of Repair, Ribonucleotide Reductases

العلاقة: Makale - Uluslararası Hakemli Dergi; Clinical and Translational Oncology; Çubukçu, E. vd. (2011). ''Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer: Implications for patient outcome''. Clinical and Translational Oncology, 13(11), 826-830.; https://doi.org/10.1007/s12094-011-0741-7Test; https://link.springer.com/article/10.1007/s12094-011-0741-7Test; http://hdl.handle.net/11452/24546Test; 000297518700012; 2-s2.0-84856052532; 826; 830; 13; 11

الإتاحة: https://doi.org/10.1007/s12094-011-0741-7Test
http://hdl.handle.net/11452/24546Test

المساهمون: Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı., orcid:0000-0002-9732-5340, Çubukçu, Erdem, Ölmez, Ömer Fatih, Saraydaroǧlu, Özlem, Akçalı, Ünsal, Kanat, Özkan, Kurt, Ender, Evrensel, Türkkan, Manavoǧlu, Osman, AAJ-1027-2021, AAH-9701-2021, 53986153800, 26435400000, 15074395500, 16027743900, 55881548500, 7006207332, 6603942124, 6602587152

مصطلحات موضوعية: Oncology, Non-small-cell lung cancer, Excision repair cross-complementing 1, Immunohistochemistry, Prognosis, Dna-repair, Chemotherapy, Messenger-RNA, Biomarkers, Resistance, Therapy, Gene, Adult, Aged, Antineoplastic agents, Carcinoma, non-small-cell lung, adjuvant, Cisplatin, Disease-free survival, DNA-binding proteins, Endonucleases, Female, Humans, Lung neoplasms, Male, Middle aged, DNA Repair, Value of Repair, Ribonucleotide Reductases

العلاقة: Makale - Uluslararası Hakemli Dergi; Clinical and Translational Oncology; Çubukçu, E. vd. (2011). ''Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer: Implications for patient outcome''. Clinical and Translational Oncology, 13(11), 826-830.; https://doi.org/10.1007/s12094-011-0741-7Test; https://link.springer.com/article/10.1007/s12094-011-0741-7Test; http://hdl.handle.net/11452/24546Test; 000297518700012; 2-s2.0-84856052532; 826; 830; 13; 11

الإتاحة: https://doi.org/10.1007/s12094-011-0741-7Test
http://hdl.handle.net/11452/24546Test